HOME >> MEDICINE >> NEWS
Stents that release medication appear more effective than traditional stents

A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

Sirolimus, a substance that is thought to help prevent reclosure of coronary arteries, can be released from certain types of stents (metal devices inserted to keep a coronary artery open after angioplasty) to greatly reduce the need for target-vessel revascularization (TVR) compared with bare-metal stents (i.e., stents without medication), according to background information in the article. These drug-eluting stents have the potential to further improve long-term clinical outcome after primary percutaneous coronary intervention (PCI), such as angioplasty. However, the lack of randomized trials to assess the safety and long-term efficacy of sirolimus-eluting stent implantation in patients with acute ST-segment elevation (a certain measurement on an electrocardiogram) myocardial infarction (STEMI), in conjunction with the expected financial consequences, currently limit use of sirolimus-eluting stents in this setting. Current clinical guidelines specifically recommend the drug abciximab during primary PCI. At current European list prices, the use of the drug tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs. bare-metal stents.

Marco Valgimigli, M.D., of the University of Ferrara, Italy and colleagues compared angiographic and clinical outcomes for the treatments of high-dose tirofiban plus sirolimus-eluting stenting vs. a current preferred strategy for STEMI treatment, pretreatment with abciximab plus bare-metal stenting. The STRATEGY trial included 175 patients presenting to a single referral center in Italy with STEMI or presumed new left bundle-branch block between March 6, 2003 and April 23, 2004. Patients received either tirofiban regimen plus sirolimus-eluting stenting (n = 87) or abciximab pl
'"/>

Contact: Marco Valgimigli
vlgmrc@unife.it
JAMA and Archives Journals
3-May-2005


Page: 1 2 3

Related medicine news :

1. ACC/AHA release revised UA/NSTEMI guidelines
2. NIAID releases MDR/XDR Tuberculosis research agenda
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. JRRD releases single-topic issue on pain and pain management
5. New prostate cancer clinical guidelines to be released
6. Physicians should be able to review performance rates before release
7. New reflux guidelines released
8. Groundbreaking principles on sexual orientation and human rights released
9. American College of Physicians releases new patient education resources
10. Joint Principles of PC-MH released by organizations representing more than 300,000 physicians
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
(Date:10/30/2014)... new vaccine that could help prevent some cases of ... Food and Drug Administration on Wednesday. Trumenba is ... and 25 from invasive meningococcal disease caused by ... can infect the bloodstream (sepsis) and the lining that ... leading cause of bacterial meningitis, and infection can occur ...
(Date:10/30/2014)... standard of care for children facing acute myeloid leukemia ... in the latest edition of the New England ... John Wagner, Jr., M.D., director of the Pediatric Blood ... and a researcher in the Masonic Cancer Center, University ... and myelodysplastic syndrome who received transplants of either one ...
(Date:10/29/2014)... 2014 – Many of the women at first acted surprised. ... to researchers why they had not used the study products ... prevention trial that, as a likely consequence, did not find ... effective. , The women were among 127 former VOICE ... D, agreed to take part in in-depth interviews and/or focus ...
Breaking Medicine News(10 mins):Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... Oct. 30, 2014   ViaDerma, Inc. ... bringing new products to market, has recently released ... TetraStem is a topical liquid tetracycline-based antibiotic that ... can convert oral medication active ingredients into topical ... first aid antibiotic to help prevent skin infection ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014  Nektar ... financial results for the third quarter ended September 30, ... of U.S.-based financial markets. Howard Robin , president ... to review the results beginning at 5:00 p.m. Eastern ... The press release and a live audio-only Webcast of ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
Cached News: